Julie So-Young Kim net worth and biography

Julie Kim Biography and Net Worth

Representative Director – President and CEO of Takeda Pharmaceutical

Julie Kim is president, chief executive officer (CEO) and representative director of Takeda. She was elected by shareholders and appointed by the Board of Directors in June 2026. She joined the company in 2019 through the acquisition of Shire and held several executive-level roles, including president of the Plasma-Derived Therapies Business Unit and president of the U.S. Business Unit before becoming CEO-elect in 2025.

Julie is leading Takeda into its next era to make an expanded impact on the lives of patients and bring increased value to its shareholders. The company is launching multiple new products while advancing the most robust pipeline in the company’s history and transforming itself through advanced technology to operate with speed and growth.

Prior to Takeda, Julie held roles of increasing responsibility at Baxter, Baxalta and Shire spanning global, regional and country-level roles across a variety of therapeutic areas and markets. Her global outlook, a result of having worked and lived in many countries and regions, including the U.K., Switzerland, China's Hong Kong and the U.S., has helped her foster diverse teams to enable inclusive decision-making that keeps the patient at the center.

A committed community and industry leader, Julie was appointed by the Mayor of Boston to the Board of Trustees of the Boston Public Library, one of the most iconic and respected institutions in the city. She also serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), leading the International Committee, and is a member of the Council of Korean Americans.

Julie holds an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree in economics from Dartmouth College. Julie splits her time between Boston and Tokyo, where Takeda is headquartered.

What is Julie So-Young Kim's net worth?: The estimated net worth of Julie So-Young Kim is at least $6.82 million as of August 10th, 2026. Ms. Kim owns 391,489 shares of Takeda Pharmaceutical stock worth more than $6,819,738 as of August 13th. This net worth estimate does not reflect any other investments that Ms. Kim may own. Learn More about Julie So-Young Kim's net worth.
How do I contact Julie So-Young Kim?: The corporate mailing address for Ms. Kim and other Takeda Pharmaceutical executives is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. Takeda Pharmaceutical can also be reached via phone at (166) 204-2111 and via email at [email protected]. Learn More on Julie So-Young Kim's contact information.
Has Julie So-Young Kim been buying or selling shares of Takeda Pharmaceutical?: In the last ninety days, Julie So-Young Kim has sold $1,523,439.00 in shares of Takeda Pharmaceutical stock. Most recently, Julie So-Young Kim sold 89,090 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a transaction totalling $1,523,439.00. Following the completion of the sale, the chief executive officer now directly owns 391,489 shares of the company's stock, valued at $6,694,461.90. Learn More on Julie So-Young Kim's trading history.
Who are Takeda Pharmaceutical's active insiders?: Takeda Pharmaceutical's insider roster includes Julie Kim (Representative Director – President and CEO), and Giles Platford (President, International Business Unit). Learn More on Takeda Pharmaceutical's active insiders.
Are insiders buying or selling shares of Takeda Pharmaceutical?: During the last twelve months, insiders at the sold shares 10 times. They sold a total of 430,094 shares worth more than $7,354,607.40. The most recent insider tranaction occured on August, 10th when insider Ramy Riad Ahmed Ibrahim sold 7,277 shares worth more than $124,436.70. Insiders at Takeda Pharmaceutical own 0.0% of the company. Learn More about insider trades at Takeda Pharmaceutical.
Information on this page was last updated on 8/10/2026.

Julie So-Young Kim Insider Trading History at Takeda Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2026	Sell	89,090	$17.10	$1,523,439.00	391,489

Julie So-Young Kim Buying and Selling Activity at Takeda Pharmaceutical

Takeda Pharmaceutical Company Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Today's Range

Now: $17.42

$17.35

$17.47

50 Day Range

MA: $16.49

$15.41

$17.78

2 Week Range

Now: $17.42

$12.99

$18.90

Volume

2,004,364 shs

Average Volume

4,402,927 shs

Market Capitalization

$55.82 billion

P/E Ratio

51.24

Dividend Yield

2.75%

Beta

N/A